Siric > SIRIC > Colorectal cancer: from the improvement of current treatments toward therapeutic innovation
Coordonnateur programme CCR

Coordinated by Prof. Antoine ADENIS (digestive oncologist at the MHI) and Dr. Philippe JAY (head of a research team at the IGF), this research program brings together the expertise of some fifteen teams of biologists from Montpellier’s biomedical research institutes, the network of digestive oncologists at the MHI and the Montpellier University Hospital, and groups of researchers in the human and social sciences from Montpellier universities.

Main goals of this program

With nearly 43,000 new cases per year in France, colorectal cancer is the 2nd most common cancer in women and the 3rd most common in men. It is also the leading digestive cancer.

The actions of this programme are structured around three main axes:

Axis 1: Basic and preclinical research: from the healthy intestinal crypt to the metastatis, is one of the main objectives of this Programme. This work builds on the resources and research tools generated by the previous SIRIC program, which made it possible to create new experimental models and collect tumour fragments and blood samples from nearly 1,500 colorectal cancer patients. The implementation at the IRCM of the latest version of CyTOF will in particular make it possible to accelerate research on tumour heterogeneity phenomena and the cellular subtypes that constitute a tumour and its environment.

Axis 2: Clinical and translational research: from residual disease to relapse. Accelerate translational research for the management of colorectal cancer, particularly for early detection, or to predict response to treatment in rectal cancer, or when the disease is at an advanced stage in the form of peritoneal carcinosis.

Axis 3: Human & social sciences : from prevention to supportive care in CRC. This program also integrates research in the humanities and social sciences on prevention and supportive care, in order to better understand the risk factors associated with the development of colorectal cancer, as well as the impact of treatments in patients’ real lives.